CAR T-Cell Therapy Market Research, 2032

The CAR T-cell therapy market size was valued at $2.6 billion in 2022 and is estimated to reach $35.9 billion by 2032, exhibiting a CAGR of 28.5% from 2023 to 2032.

The growth of the CAR T-cell therapy market is driven by increase in prevalence of leukemia across the globe, increase in investment for research and development of the new CAR T-cell therapy, and high effectivity of CAR T-cell therapy over other conventional drugs for cancer treatment. According to the Leukemia Research Foundation,  an estimate of6,660 new cases of acute lymphoblastic leukemia were diagnosed in 2022. This rise in cases of leukemia has propelled the demand for CAR T-cell therapy, which drives the market growth.

Key Takeaways:

• By drug type, the axicabtagene ciloleucel segment held the largest share in the CAR T-cell therapy market in 2022.
• By indication, the lymphoma segment held the largest share in the CAR T-cell therapy market in 2022.
• By end user, the cancer centers segment is expected to show the fastest market growth during the forecast period.
• Region-wise, North America held the largest market share in 2022.

CAR T-cell therapy represents a groundbreaking approach in the field of cancer treatment. This innovative immunotherapy harnesses the power of the patient's own immune system to combat cancer. CAR T-cell therapy has shown remarkable success in treating certain types of hematologic malignancies, such as certain forms of leukemia and lymphoma, demonstrating its potential as a transformative therapeutic option for patients who have not responded to conventional treatments.

Market Dynamics

Rise in prevalence of leukemia, surge in research and development activities to develop new CAR T-cell therapy, and high effectivity of CAR T-cell therapy over other conventional drugs for cancer treatment are the key factors driving the growth of the market.

Rise in prevalence of leukemia has emerged as a pivotal driver propelling the growth of the CAR T-cell therapy market. Leukemia, characterized by the uncontrolled proliferation of abnormal white blood cells, has witnessed a substantial rise in its incidence over recent years. For instance, according to American Cancer Society, in 2022, it was estimated that approximately 60,650 new cases of leukemia were diagnosed in the U.S. This surge can be attributed to a myriad of factors, including genetic predispositions, environmental exposures, and lifestyle changes. CAR T-cell therapy, a groundbreaking immunotherapy, has gained prominence as a promising solution for leukemia treatment. This therapeutic approach involves the modification of a patient's own T cells to express CARs, enabling them to recognize and eliminate cancer cells more effectively.

The remarkable success observed in clinical trials, particularly in treating B-cell acute lymphoblastic leukemia (ALL) and other hematological malignancies, has catapulted CAR T-cell therapy to the forefront of cancer treatment. Consequently, rise in leukemia cases has not only underscored the urgent need for advanced and targeted therapies but has also positioned CAR T-cell therapy as a transformative and increasingly indispensable component in the ongoing battle against leukemia. Thus, rise in prevalence of leukemia is expected to significantly contribute in the growth of the market.

Furthermore, the CAR T-cell therapy has witnessed significant surge in research and development activities, contributing significantly in the growth of the market. Researchers and pharmaceutical companies are investing extensively in the development of novel CAR T-cell therapies, recognizing their potential to revolutionize the field of oncology. This heightened interest stems from the remarkable success stories associated with CAR T-cell therapy, which has demonstrated unprecedented efficacy in treating certain types of hematologic malignancies, particularly B-cell malignancies.

According to National Cancer Institute, it was reported that since 2017, six CAR T-cell therapies have been approved by the Food and Drug Administration (FDA). All are approved for the treatment of blood cancers, including lymphomas, some forms of leukemia, and, most recently, multiple myeloma. Thus, surge in research and development in the field of CAR T-cell therapies is expected to drive the growth of the market.

In addition, high effectivity of CAR T-cell therapy over other conventional drugs for cancer treatment is expected to drive the growth of the market. Unlike conventional treatments such as chemotherapy or radiation, which often exhibit systemic toxicity and limited specificity, CAR T-cell therapy targets cancer cells directly, offering a highly effective and targeted solution. CAR T-cell therapy involves genetically modifying a patient's T-cells to express chimeric antigen receptors (CARs), which specifically recognize and bind to cancer cells. This targeted approach significantly reduces damage to healthy cells and minimizes adverse side effects commonly associated with traditional treatments.

Clinical trials and real-world applications of CAR T-cell therapy have demonstrated unprecedented success, especially in hematological malignancies such as certain types of leukemia and lymphomas. Patients who have undergone CAR T-cell therapy often experience sustained remissions, offering a potential cure rather than merely managing the disease.

For instance, according to a 2023 report by National Library of Medicine, it was reported that CAR-T cells, have generated extraordinary results in phase I/II clinical trials in the treatment of CD19+ B-cell hematological malignancies. In addition, according to a 2022 report by National Cancer Institute, it was reported that, in two large clinical trials, CAR T-cell therapy proved to be more effective than the standard treatment for patients with non-Hodgkin lymphoma whose cancer returned after their initial, or first-line, chemotherapy. Thus, high efficiency of the CAR T-cell therapy in treating the lymphoma is expected to drive the growth of the market.

However, high cost of CAR T-cell therapy might restrain the growth of the market. The intricate and highly personalized nature of CAR T-cell therapy, involving the extraction and genetic modification of a patient's own T cells to specifically target cancer cells, contributes substantially to the elevated costs.

The complex and resource-intensive manufacturing processes, including the genetic engineering techniques employed to modify the T cells, as well as the rigorous quality control measures implemented to ensure the safety and efficacy of the therapy, drive increase production costs significantly.

In addition, the need for specialized infrastructure, such as cleanroom facilities, and the intricate coordination required for timely collection, modification, and reinfusion of T cells further contribute to the overall expenses. As a result, the high cost becomes a formidable hurdle for widespread adoption and accessibility, limiting the potential benefits of CAR T-cell therapy to a select few who can afford it.

Segmental Overview

The CAR T-cell therapy market is segmented on the basis of drug type, indication, end user, and region. On the basis of drug type, the market is classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. By indication, the market is segregated into lymphoma, acute lymphocytic leukemia, and others. Depending on end user, it is fragmented into hospitals and cancer treatment centers. Region-wise, the market is analyzed across North America (the U.S., and Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

By Drug Type

On the basis of drug type, the CAR T-cell therapy market is categorized into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. The axicabtagene ciloleucel segment dominated the global market in 2022 owing to high adoption of axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

[DRUGTYPEGRAPH]

By Indication:

On the basis of indication, the market is categorized into lymphoma, acute lymphocytic leukemia, and others. The lymphoma segment dominated the global market in 2022 owing to high prevalence of lymphoma globally. However, the acute lymphocytic leukemia segment is expected to register the fastest growth during the forecasted period, owing to research and development activities to develop CAR T-cell therapy to treat acute lymphocytic leukemia.

[INDICATIONGRAPH]

By End User:

On the basis of end user, the market is categorized into hospitals and cancer treatment centers. The hospitals segment dominated the market in 2022, owing to high patient base getting cancer treatment in hospitals. However, the cancer treatment centers segment is expected to register the fastest growth during the forecast period, owing to availability of a wide range of choice of treatment and increase in the number of cancer centers in some developing nations.

[ENDUSERGRAPH]

By Region

The CAR T-cell therapy market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market share in terms of revenue in 2022. The growth in this region is mainly attributed to high R&D activities to develop new CAR T-cell therapies, and strong presence of key players in the region. In addition, the presence of several major players, such as Bristol-Myers Squibb, Johnson & Johnson, Gilead Sciences, and Intellia Therapeutics., and Pfizer Inc. contribute to the market growth in the region.

Europe is expected to grow at the highest rate during the forecast period. This is attributed to high prevalence rate of cancer, a large and diverse population, improving healthcare infrastructure, and rise in geriatric population as they are more prone to the cancer disease. In addition, the rise in research and clinical trials, growing awareness, and surge in pharmaceutical and biotechnology investments for the development of novel drugs are the factors that drive the market growth in this region.

[REGIONGRAPH]

Competition Analysis

Competitive analysis and profiles of the major players in the CAR T-cell therapy market growth, such as Autolus Therapeutics, 2Seventy Bio, Inc., Bristol-Myers Squibb, Gilead Sciences, Intellia Therapeutics, Caribou Biosciences, Inc., Cartesian Therapeutics, Inc, Novartis AG, Pfizer, and Johnson and Johnson. Major players have adopted clinical trials, product approval, collaboration, strategic alliance and  merger as a key developmental strategy to improve the product portfolio and gain a strong foothold in the CAR T-cell therapy market.

Recent Product Approvals in the CAR T-cell therapy market

• In December 2023, Bristol-Myers Squibb announced that it received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for patients with relapsed or refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

Recent Clinical Trials in the CAR T-cell therapy market

• In May 2023, Autolus Therapeutics plc announced that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been selected for an oral presentation at the European Hematology Association (EHA) 2023 Congress.

Recent Collaboration in the CAR T-cell therapy market

• In April 2022, Autolus Therapeutics plc, announced that it has collaborated with Cardinal Health Inc. to support the launch and commercialization of its CAR T-cell therapies in the U.S., subject to FDA approval.

Recent Strategic Alliance in the CAR T-cell therapy market

• In September 2023, 2seventy bio, Inc. and JW Therapeutics announced their intention to expand their strategic alliance. The companies intend to add up to two additional candidates from the 2seventy portfolio, one in solid tumor indications using T-cell receptor (TCR) based technology and a second in autoimmune disease using a CAR T cell approach.

Recent Merger in the CAR T-cell therapy market

• In November 2023, Selecta Biosciences, Inc. announced that it merged with Cartesian Therapeutics, Inc. With the cash from both companies at closing and the proceeds of the concurrent private financing, the combined company is expected to have over $110 million on hand to support the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of MG, as well as the advancement of additional RNA cell therapy programs.

 Key Market Segments

• By Drug type
  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Others
• By Indication
  • Lymphoma
  • Acute Lymphocytic Leukemia
  • Others
• By End user
  • Hospitals
  • Cancer Treatment Centers
• By Region
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

 
Key Market Players

• Bluebird Bio, Inc.
• Merck & Co., Inc.
• Celyad Oncology
• Celgene Corporation
• Miltenyi Biotech
• Novartis AG
• Cartesian Therapeutics, Inc.
• Bristol-Myers Squibb
• Intellia Therapeutics
• Gilead Sciences, Inc. (Kite Pharma Inc.)
• Cellectis
• Pfizer, Inc.
• Sorrento Therapeutics, Inc.
• Autolus Therapeutics
• Caribou Biosciences, Inc.
• Juno Therapeutics, Inc.

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments

1.3.1.    List of key players profile in the report

1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools and models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings of the study
2.2.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Porters five forces analysis
3.3.    Market dynamics

3.3.1.    Drivers

3.3.1.1.    Surge in prevalence of cancer
3.3.1.2.    High effectivity of CAR T-cell therapy over other conventional drugs for cancer treatment
3.3.1.3.    Increase in investment and funding for research in CAR T-Cell therapy

3.3.2.    Restraints

3.3.2.1.    High cost of CAR T-cell therapies

3.3.3.    Opportunities

3.3.3.1.    High R&D activities to develop CAR T-cell therapeutics

3.4.    Impact analysis

3.5.3 Recession Impact Analysis

3.6.    List of Startup companies with series A, B funding in North America
3.7.    List of 50 Pharmaceutical and Biotechnology Companies

CHAPTER 4:    CAR T-CELL THERAPY, BY DRUG TYPE

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Axicabtagene ciloleucel

4.2.1.    Key market trends, growth factors, and opportunities
4.2.2.    Market size and forecast, by region
4.2.3.    Market analysis, by country

4.3.    Tisagenlecleucel

4.3.1.    Key market trends, growth factors, and opportunities
4.3.2.    Market size and forecast, by region
4.3.3.    Market analysis, by country

4.4.    Brexucabtagene Autoleuce

4.4.1.    Key market trends, growth factors, and opportunities
4.4.2.    Market size and forecast, by region
4.4.3.    Market analysis, by country

4.5.    Others

4.5.1.    Key market trends, growth factors, and opportunities
4.5.2.    Market size and forecast, by region
4.5.3.    Market analysis, by country

CHAPTER 5:    CAR T-CELL THERAPY, BY INDICATION

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Lymphoma

5.2.1.    Market size and forecast, by region
5.2.2.    Market analysis, by country

5.3.    Acute Lymphocytic Leukemia

5.3.1.    Market size and forecast, by region
5.3.2.    Market analysis, by country

5.4.    Others

5.4.1.    Market size and forecast, by region
5.4.2.    Market analysis, by country

CHAPTER 6:    CAR T-CELL THERAPY, BY END USER

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    Hospitals

6.2.1.    Market size and forecast, by region
6.2.2.    Market analysis, by country

6.3.    Cancer Treatment Centers

6.3.1.    Market size and forecast, by region
6.3.2.    Market analysis, by country

CHAPTER 7:    CAR T-CELL THERAPY MARKET, BY REGION

7.1.    Overview

7.1.1.    Market size and forecast

7.2.    North America

7.2.1.    Key market trends, growth factors, and opportunities
7.2.2.    North America CAR T-cell therapy market, by country

7.2.2.1.    U.S.

7.2.2.1.1.    Market size and forecast, by drug type
7.2.2.1.2.    Market size and forecast, by indication
7.2.2.1.3.    Market size and forecast, by end user

7.2.2.2.    Canada

7.2.2.2.1.    Market size and forecast, by drug type
7.2.2.2.2.    Market size and forecast, by indication
7.2.2.2.3.    Market size and forecast, by end user

7.2.3.    North America market size and forecast, by drug type
7.2.4.    North America market size and forecast, by type
7.2.5.    North America market size and forecast, by end user

7.3.    Europe

7.3.1.    Key market trends, growth factors, and opportunities
7.3.2.    Europe CAR T-cell therapy market, by country

7.3.2.1.    Germany

7.3.2.1.1.    Market size and forecast, by drug type
7.3.2.1.2.    Market size and forecast, by type
7.3.2.1.3.    Market size and forecast, by end user

7.3.2.2.    France

7.3.2.2.1.    Market size and forecast, by drug type
7.3.2.2.2.    Market size and forecast, by type
7.3.2.2.3.    Market size and forecast, by end user

7.3.2.3.    UK

7.3.2.3.1.    Market size and forecast, by drug type
7.3.2.3.2.    Market size and forecast, by indication
7.3.2.3.3.    Market size and forecast, by end user

7.3.2.4.    Rest of Europe

7.3.2.4.1.    Market size and forecast, by drug type
7.3.2.4.2.    Market size and forecast, by indication
7.3.2.4.3.    Market size and forecast, by end user

7.3.3.    Europe market size and forecast, by drug type
7.3.4.    Europe market size and forecast, by indication
7.3.5.    Europe market size and forecast, by end user

7.4.    Asia-Pacific

7.4.1.    Key market trends, growth factors, and opportunities
7.4.2.    Asia-Pacific CAR T-cell therapy market, by country

7.4.2.1.    Japan

7.4.2.1.1.    Market size and forecast, by drug type
7.4.2.1.2.    Market size and forecast, by indication
7.4.2.1.3.    Market size and forecast, by end user

7.4.2.2.    China

7.4.2.2.1.    Market size and forecast, by drug type
7.4.2.2.2.    Market size and forecast, by indication
7.4.2.2.3.    Market size and forecast, by end user

7.4.2.3.    Rest of Asia-Pacific

7.4.2.3.1.    Market size and forecast, by drug type
7.4.2.3.2.    Market size and forecast, by indication
7.4.2.3.3.    Market size and forecast, by end user

7.4.3.    Asia-Pacific market size and forecast, by drug type
7.4.4.    Asia-Pacific market size and forecast, by indication
7.4.5.    Asia-Pacific market size and forecast, by end user

7.5.    LAMEA

7.5.1.    Key market trends, growth factors, and opportunities
7.5.2.    LAMEA CAR T-cell therapy market, by country

7.5.2.1.    Latin America

7.5.2.1.1.    Market size and forecast, by drug type
7.5.2.1.2.    Market size and forecast, by indication
7.5.2.1.3.    Market size and forecast, by end user

7.5.2.2.    Middle East and Africa

7.5.2.2.1.    Market size and forecast, by drug type
7.5.2.2.2.    Market size and forecast, by indication
7.5.2.2.3.    Market size and forecast, by end user

7.5.3.    LAMEA market size and forecast, by drug type
7.5.4.    LAMEA market size and forecast, by indication
7.5.5.    LAMEA market size and forecast, by end user

CHAPTER 8:    COMPETITION LANDSCAPE

8.1.    Top winning strategies
8.2.    Product mapping
8.3.    Competitive dashboard
8.4.    Competitive heatmap
8.5.    Key developments

8.5.1.    Merger
8.5.2.    Collaboration
8.5.3.    Clinical Trials
8.5.4.    Product Approval
8.5.5.    Strategic Alliance

8.6.    Top player positioning, 2022-2023

CHAPTER 9:    COMPANY PROFILES

9.1.    BRISTOL-MYERS SQUIBB COMPANY

9.1.1.    Company overview
9.1.2.    Key executives
9.1.3.    Company snapshot
9.1.4.    Operating business segments
9.1.5.    Product portfolio
9.1.6.    Business Performance
9.1.7.    Key strategic moves and developments

9.2.    PFIZER INC.

9.2.1.    Company overview
9.2.2.    Key executives
9.2.3.    Company snapshot
9.2.4.    Operating business segments
9.2.5.    Product portfolio
9.2.6.    Business Performance
9.2.7.    Key strategic moves and developments

9.3.    GILEAD SCIENCES, INC

9.3.1.    Company overview
9.3.2.    Key executives
9.3.3.    Company snapshot
9.3.4.    Operating business segment
9.3.5.    Product portfolio
9.3.6.    Business Performance
9.3.7.    Key strategic moves and developments

9.4.    NOVARTIS AG

9.4.1.    Company overview
9.4.2.    Key executives
9.4.3.    Company snapshot
9.4.4.    Operating business segments
9.4.5.    Product portfolio
9.4.6.    Business Performance
9.4.7.    Key strategic moves and developments

9.5.    INTELLIA THERAPEUTICS, INC

9.5.1.    Company overview
9.5.2.    Key executives
9.5.3.    Company snapshot
9.5.4.    Operating business segment
9.5.5.    Product portfolio
9.5.6.    Key strategic moves and developments

9.6.    JOHNSON & JOHNSON

9.6.1.    Company overview
9.6.2.    Key executives
9.6.4.    Company snapshot
9.6.5.    Operating business segments:
9.6.7.    Product portfolio
9.6.8.    Business Performance
9.6.9.    Key strategic moves and developments

9.7.    AUTOLUS THERAPEUTICS PLC

9.7.1.    Company overview
9.7.2.    Key executives
9.7.4.    Company snapshot
9.7.5.    Operating business segment
9.7.6.    Product portfolio
9.7.7.    Business Performance
9.7.8.    Key strategic moves and developments

9.8.SEVENTY BIO, INC

9.8.1.    Company overview
9.8.2.    Key executives
9.8.3.    Company snapshot
9.8.4.    Operating business segments
9.8.5.    Product portfolio
9.8.6.    . Key strategic moves and developments

9.9.    CARIBOU BIOSCIENCES, INC

9.9.1.    Company overview
9.9.2.    Key executives
9.9.3.    Company snapshot
9.9.4.    Operating business segments
9.9.5.    Product portfolio
9.9.6.    Business Performance
9.9.7.    Key strategic moves and developments

9.10.    CARTESIAN THERAPEUTICS, INC

9.10.1.    Company overview
9.10.2.    Key executives
9.10.3.    Company snapshot
9.10.4.    Operating business segments
9.10.5.    Product portfolio
9.10.6.    Key strategic moves and developments

LIST OF TABLES

TABLE 01.    CAR T-CELL THERAPY, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02.    CAR T-CELL THERAPY MARKET FOR AXICABTAGENE CILOLEUCEL, BY REGION, 2022–2032 ($MILLION)
TABLE 03.    CAR T-CELL THERAPY MARKET FOR TISAGENLECLEUCEL, BY REGION, 2022–2032 ($MILLION)
TABLE 04.    CAR T-CELL THERAPY MARKET FOR BREXUCABTAGENE AUTOLEUCE, BY REGION, 2022–2032 ($MILLION)
TABLE 05.    CAR T-CELL THERAPY MARKET FOR OTHERS, BY REGION, 2022–2032 ($MILLION)
TABLE 06.    CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 07.    CAR T-CELL THERAPY MARKET FOR LYMPHOMA INDICATION, BY REGION, 2022–2032 ($MILLION)
TABLE 08.    CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOMA INDICATION, BY REGION, 2022–2032 ($MILLION)
TABLE 09.    CAR T-CELL THERAPY MARKET FOR OTHERS INDICATION, BY REGION, 2022–2032 ($MILLION)
TABLE 10.    CAR T-CELL THERAPY, BY END USER, 2022-2032 ($MILLION)
TABLE 11.    CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2022–2032 ($MILLION)
TABLE 12.    CAR T-CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2022–2032 ($MILLION)
TABLE 01.    CAR T-CELL THERAPY MARKET, BY REGION, 2022–2032 ($MILLION)
TABLE 02.    NORTH AMERICA CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2032 ($MILLION)
TABLE 03.    U.S. CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 04.    U.S. CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2032 ($MILLION)
TABLE 05.    U.S. CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 06.    CANADA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 07.    CANADA CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2032 ($MILLION)
TABLE 08.    CANADA CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 09.    NORTH AMERICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 10.    NORTH AMERICA CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2032 ($MILLION)
TABLE 11.    NORTH AMERICA CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 12.    EUROPE CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2032 ($MILLION)
TABLE 13.    GERMANY CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 14.    GERMANY CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 15.    GERMANY CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 16.    FRANCE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 17.    FRANCE CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 18.    FRANCE CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 19.    UK CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 20.    UK CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 21.    UK CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 22.    REST OF EUROPE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 23.    REST OF EUROPE CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 24.    REST OF EUROPE CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 25.    EUROPE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 26.    EUROPE CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 27.    EUROPE CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 28.    ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2032 ($MILLION)
TABLE 29.    JAPAN CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 30.    JAPAN CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 32.    JAPAN CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 33.    CHINA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 34.    CHINA CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 35.    CHINA CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 36.    REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 37.    REST OF ASIA-PACIFIC CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 38.    REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 39.    ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 40.    ASIA-PACIFIC CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 41.    ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 42.    LAMEA CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2032 ($MILLION)
TABLE 43.    LATIN AMERICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021–2031 ($MILLION)
TABLE 44.    LATIN AMERICA CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 45.    LATIN AMERICA CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 46.    MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 47.    MIDDLE EAST AND AFRICA CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 48.    MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 49.    LAMEA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 ($MILLION)
TABLE 50.    CAR T-CELL THERAPY, BY INDICATION, 2022-2032 ($MILLION)
TABLE 51.    LAMEA CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 ($MILLION)
TABLE 52.    BRISTOL MYERS SQUIBB.: KEY EXECUTIVES
TABLE 53.    BRISTOL MYERS SQUIBB.: COMPANY SNAPSHOT
TABLE 54.    BRISTOL MYERS SQUIBB. PRODUCT SEGMENT
TABLE 55.    BRISTOL MYERS SQUIBB.: PRODUCT PORTFOLIO
TABLE 56.    BRISTOL MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 57.    PFIZER INC.: KEY EXECUTIVES
TABLE 58.    PFIZER INC.: COMPANY SNAPSHOT
TABLE 59.    PFIZER INC. PRODUCT SEGMENTS
TABLE 60.    PFIZER INC.: PRODUCT PORTFOLIO
TABLE 61.    PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 62.    GILEAD SCIENCES, INC.: KEY EXECUTIVES
TABLE 63.    GILEAD SCIENCES, INC: COMPANY SNAPSHOT
TABLE 64.    GILEAD SCIENCES, INC PRODUCT SEGMENT
TABLE 65.    GILEAD SCIENCES, INC: PRODUCT PORTFOLIO
TABLE 66.    GILEAD SCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 67.    NOVARTIS AG: KEY EXECUTIVES
TABLE 68.    NOVARTIS AG: COMPANY SNAPSHOT
TABLE 69.    NOVARTIS AG PRODUCT SEGMENTS
TABLE 70.    NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 71.    NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 72.    INTELLIA THERAPEUTIC, INC.: KEY EXECUTIVES
TABLE 73.    INTELLIA THERAPEUTIC, INC.: COMPANY SNAPSHOT
TABLE 74.    INTELLIA THERAPEUTIC, INC. PRODUCT SEGMENT
TABLE 75.    INTELLIA THERAPEUTIC, INC.: PRODUCT PORTFOLIO
TABLE 76.    JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 77.    JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 78.    JOHNSON & JOHNSON PRODUCT SEGMENTS
TABLE 79.    JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 80.    JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 81.    AUTOLUS THERAPEUTICS: KEY EXECUTIVES
TABLE 82.    AUTOLUS THERAPEUTICS: COMPANY SNAPSHOT
TABLE 83.    AUTOLUS THERAPEUTICS SEGMENT
TABLE 84.    AUTOLUS THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 85.SEVENTY BIO, INC.: KEY EXECUTIVES
TABLE 86.SEVENTY BIO, INC.: COMPANY SNAPSHOT
TABLE 87.SEVENTY BIO, INC. PRODUCT SEGMENTS
TABLE 88.SEVENTY BIO, INC.: PRODUCT PORTFOLIO
TABLE 89.    CARIBOU BIOSCIENCES, INC.: KEY EXECUTIVES
TABLE 90.    CARIBOU BIOSCIENCES, INC COMPANY SNAPSHOT
TABLE 91.    CARIBOU BIOSCIENCES, INC.: PRODUCT SEGMENTS
TABLE 92.    CARIBOU BIOSCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 93.    CARTESIAN THERAPEUTICS, INC: KEY EXECUTIVES
TABLE 94.    CARTESIAN THERAPEUTICS, INC: COMPANY SNAPSHOT
TABLE 95.    CARTESIAN THERAPEUTICS, INC.: PRODUCT SEGMENTS
TABLE 96.    CARTESIAN THERAPEUTICS, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    EXECUTIVE SUMMARY
FIGURE 02.    CAR T-CELL THERAPY MARKET SEGMENTATION
FIGURE 03.    LOW BARGANING POWER OF SUPPLIERS
FIGURE 04.    MODERATE BARGANING POWER OF BUYERS
FIGURE 05.    MODERATE THREAT OF SUBSTITUTION
FIGURE 06.    LOW THREAT OF NEW ENTRANTS
FIGURE 07.    HIGHLY COMPETITIVE RIVALRY
FIGURE 08.    IMPACT ANALYSIS
FIGURE 09.    CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2022–2032 (%)
FIGURE 10.    COMPARATIVE ANALYSIS OF CAR T-CELL THERAPY MARKET FOR AXICABTAGENE CILOLEUCEL, BY COUNTRY, 2022 & 2032 ($MILLION)
FIGURE 11.    COMPARATIVE ANALYSIS OF CAR T-CELL THERAPY MARKET FOR TISAGENLECLEUCEL, BY COUNTRY, 2022 & 2032 ($MILLION)
FIGURE 12.    COMPARATIVE ANALYSIS OF CAR T-CELL THERAPY MARKET FOR BREXUCABTAGENE AUTOLEUCE, BY COUNTRY, 2022 & 2032 ($MILLION)
FIGURE 13.    COMPARATIVE ANALYSIS OF CAR T-CELL THERAPY MARKET FOR OTHERS, BY COUNTRY, 2022 & 2032 ($MILLION)
FIGURE 14.    CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2032 (%)
FIGURE 15.    COMPARATIVE ANALYSIS OF CAR T-CELL THERAPY MARKET FOR LYMPHOMA INDICATION, BY COUNTRY,  2022 & 2032 ($MILLION)
FIGURE 16.    COMPARATIVE ANALYSIS OF CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOMA INDICATION, BY COUNTRY, 2022 & 2032 ($MILLION)
FIGURE 17.    COMPARATIVE ANALYSIS OF CAR T-CELL THERAPY MARKET FOR OTHERS INDICATION, BY COUNTRY,  2022 & 2032 ($MILLION)
FIGURE 18.    CAR T-CELL THERAPY MARKET, BY END USER, 2022–2032 (%)
FIGURE 19.    COMPARATIVE ANALYSIS OF CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022 & 2032 ($MILLION)
FIGURE 20.    COMPARATIVE ANALYSIS OF CAR T-CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY COUNTRY, 2022 & 2032 ($MILLION)
FIGURE 01.    CAR T-CELL THERAPY MARKET, BY REGION, 2021–2031 (%)
FIGURE 02.    TOP WINNING STRATEGIES, BY YEAR, 2022–2023
FIGURE 03.    TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2023 (%)
FIGURE 04.    TOP WINNING STRATEGIES, BY COMPANY, 2022–2023
FIGURE 05.    PRODUCT MAPPING OF TOP 10 KEY PLAYERS
FIGURE 06.    COMPETITIVE DASHBOARD OF TOP 10 KEY PLAYERS
FIGURE 07.    COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 08.    BRISTOL MYERS SQUIBB.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 09.    BRISTOL MYERS SQUIBB.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 10.    PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 11.    PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 12.    PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 13.    GILEAD SCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 14.    NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 15.    NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 16.    NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 17.    JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 18.    JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 19.    JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 20.    AUTOLUS THERAPEUTICS: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 21.    CARIBOU BIOSCIENCES, INC.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 22.    CARIBOU BIOSCIENCES, INC.: REVENUE SHARE BY REGION, 2022 (%)